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Hypoxia stimulates tumor angiogenesis by inducing the expression of angiogenic molecules. The negative regulators of this
process, however, are not well understood. Here, we report that hypoxia induced the expression of insulin-like growth factor
binding protein-6 (IGFBP-6), a tumor repressor, in human and rodent vascular endothelial cells (VECs) via a hypoxia-inducible
factor (HIF)-mediated mechanism. Addition of human IGFBP-6 to cultured human VECs inhibited angiogenesis in vitro. An
IGFBP-6 mutant with at least 10,000-fold lower binding affinity for IGFs was an equally potent inhibitor of angiogenesis,
suggesting that this action of IGFBP-6 is IGF-independent. The functional relationship between IGFBP-6 and vascular
endothelial growth factor (VEGF), a major hypoxia-inducible angiogenic molecule, was examined. While VEGF alone increased
angiogenesis in vitro, co-incubation with IGFBP-6 abolished VEGF-stimulated angiogenesis. The in vivo role of IGFBP-6 in
angiogenesis was tested in flk1:GFP zebrafish embryos, which exhibit green fluorescence protein in developing vascular
endothelium, permitting visualization of developing blood vessels. Injection of human IGFBP-6 mRNA reduced the number of
embryonic inter-segmental blood vessels by ~40%. This anti-angiogenic activity is conserved in zebrafish because expression
of zebrafish IGFBP-6b had similar effects. To determine the anti-angiogenic effect of IGFBP-6 in a tumor model, human Rh30
rhabdomyosarcoma cells stably transfected with IGFBP-6 were inoculated into athymic BALB/c nude mice. Vessel density was
52% lower in IGFBP-6-transfected xenografts than in vector control xenografts. These results suggest that the expression of
IGFBP-6 in VECs is up-regulated by hypoxia and IGFBP-6 inhibits angiogenesis in vitro and in vivo.
Hypoxia is widely recognized as an important driving force
for tumor angiogenesis. As tumors grow, the original vascula-
ture becomes insufﬁcient to supply oxygen to the growing tu-
mor cells, and local hypoxia develops. Hypoxia stimulates
new blood vessel formation via the induction of angiogenic
factors. This neovascularization is critical for tumor progres-
sion as it provides tumor cells with oxygen, nutrients and
growth factors.1–3 A key player in the hypoxia response is hy-
poxia-inducible factor-1 (HIF-1), which is a heterodimeric
transcription factor composed of HIF-1a and HIF-1b. While
HIF-1b (also known as ARNT) is constitutively expressed,
HIF-1a is sensitive to O2 tension. When O2 levels are high,
HIF-1a is hydroxylated by prolyl hydroxylase domain-con-
taining proteins (PHDs), then ubiquitinated and targeted for
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proteosomal degradation. In hypoxic conditions, HIF-1a
hydroxylation is inhibited, and it enters the nucleus where it
forms a dimer with HIF-1b. The dimerized HIF-1 complex
binds to hypoxia response elements (HREs) of its target
genes and promotes their transcription. HREs are present in
many angiogenic genes including vascular endothelial growth
factor (VEGF), a major angiogenic gene, and its receptor,
Flk1.4,5
Recent studies suggest that there are also negative feedback
mechanisms that inhibit angiogenesis during prolonged hy-
poxia.6 An et al.7 reported that expression of RGC32, which
inhibits VEGF- and hypoxia-induced angiogenesis, is up-regu-
lated by hypoxia. Similarly, hypoxia induces the expression of
GRS5, which inhibits VEGF-induced angiogenesis through p38
MAPK, via HIF-1 activation.8 Compared to our relatively com-
prehensive understanding of the induction of angiogenic genes
by hypoxia/HIF-1, however, the negative regulators in hy-
poxia-induced tumor angiogenesis are not well understood.
Insulin-like growth factor binding proteins (IGFBP) 1–6
bind IGFs with high afﬁnity in extracellular ﬂuids and reg-
ulate IGF actions at target tissues.9 Some IGFBPs also pos-
sess distinct biological actions that are independent of
IGFs.9 IGFBP-6 is unique among the six IGFBPs because
of its 50-fold greater afﬁnity for IGF-II, making it a rela-
tively speciﬁc inhibitor of IGF-II actions.10 Recent studies
suggest that IGFBP-6 is a tumor suppressor that inhibits
the growth of a number of IGF-II-dependent tumors.10 In
addition to its ability to bind and sequester IGF-II, recent
in vitro studies suggest that IGFBP-6 also has IGF-inde-
pendent actions.11
An early report showed that hypoxia increased IGFBP-6
mRNA levels in bovine endothelial cells,12 but expression of
IGFBP-6 and its relationship to hypoxia have not been stud-
ied in human endothelial cells. More importantly, the role of
IGFBP-6 in normal and tumor angiogenesis, if any, is
unknown. The objective of our study was therefore to test
the hypothesis that hypoxia induces IGFBP-6 gene expression
in vascular tissues, and that this induction of IGFBP-6 nega-
tively regulates hypoxia-induced tumor angiogenesis.
Material and Methods
Experimental animals
Wild type and ﬂk1:GFP transgenic zebraﬁsh (Danio rerio)
were kept at 28C under a 14:10-h light–dark photoperiod
and fed twice daily. Embryos were obtained from natural
breeding and were kept at 28.5C in embryo-rearing solution
supplemented with 0.003% (weight/volume) 2-phenylthiourea
(Sigma, St. Louis, MO).13 All experiments with zebraﬁsh were
conducted at Ocean University of China with approved pro-
tocols. Female athymic BALB/c nude mice were obtained
from the Animal Resource Centre, Western Australia.
Xenografting studies were performed at the University of
Melbourne in accordance with institutional guidelines of the
University of Melbourne and Austin and Repatriation Medi-
cal Centre Animal Ethics and Biosafety Committees.
Cell culture and hypoxia treatment
Human umbilical vein endothelial cells (HUVECs) and rat
brain vessel endothelial cells were obtained from ATCC and
maintained in 45% a-MEM (Gibco) supplemented with 45%
F-10 (Gibco), 10% fetal bovine serum (FBS), 100 U/mL peni-
cillin and 100lg/mL streptomycin. Normoxic cells (20% O2)
were maintained in a humidiﬁed-air atmosphere incubator
containing 95% air/5% CO2 at 37C. Hypoxic cells (0.1% or
1% O2) were maintained in a controlled atmosphere chamber
at 37C. Rh30 human rhabdomyosarcoma cells were stably
transfected with an empty vector or human IGFBP-6 expres-
sion plasmids and cultured using published protocols.14
Western immunoblotting
Nuclear extracts from cultured HUVECs were prepared fol-
lowing previously published procedure.15 Western immuno-
blotting analysis was carried out as reported16 using a poly-
clonal anti HIF-1a antibody (Novus Biologicals LLC,
Littleton, CO) at a dilution of 1:500. The second antibody
used was a goat anti-rabbit antibody (Kang Chen Bio-tech,
Shanghai, China) at a dilution of 1:2,000.
RT-PCR and quantitative real-time RT-PCR (qRT-PCR)
Total RNA was isolated from cultured cells using Trio Rea-
gent (Nitrogen, Carlsbad, CA). RNA (1 lg) was reverse tran-
scribed using M-MLV (Prote´ge´, Madison, WI) and oli-
go(dT)18 primer (Sangon, Shanghai, China). RT-PCR was
carried out using premix Taq polymerase (Takara, Dalian,
China) in a MyCycler Thermal Cycler (Bio-Rad, Hercules,
CA). RT-PCR products were fractionated by 1.5% agarose gel
electrophoresis, stained with ethidium bromide and photo-
graphed using a Chemidoc XRS Gel Documentation System
(Bio-Rad, Hercules, CA).
qRT-PCR was carried out in an iCycler iQ Multicolor real-
time PCR detection system (Bio-Rad Laboratories, Hercules,
CA) using SYBR Green PCR Master Mix (Applied Biosystems,
Foster City, CA). Primers used were as follows: b-actin: 50-
CCAGATCATGTTTGAGACC-30 and 50-GCCAG GTCCA-
GACGCAGG-30; human IGFBP-6: 50-ATCCGCCCAAGGAC-
GACGAG-30 50-TGCCTGGATTCCTCTGTTGGTC-30. Serial
dilutions of plasmid DNA ranging from 108 to 103 molecules/
lL for b-actin and 107 to 102 molecules/lL for human IGFBP-
6 were used to generate standard curves. After 3 min incuba-
tion at 95C, ampliﬁcation was performed as follows: 95C, 10
s, 60C, 30 s, for 40 cycles. Each assay for an unknown sample
was performed in duplicate along with the standard DNA and
negative control. The number of molecules of a particular gene
transcript was calculated based on the standard curve and nor-
malized to b-actin mRNA levels.
In vitro capillary-like tube formation assay
The effect of IGFBP-6 on angiogenesis was examined using
an in vitro tube formation assay as reported previously.17
Brieﬂy, aliquots (50 lL) of Matrigel were plated into
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individual wells of 96 well tissue culture plates and allowed
to polymerize at 37C. After incubation in serum-free me-
dium for 12 h, HUVEC cells were trypsinized and re-sus-
pended in culture medium containing 1% FBS. HUVEC cells
(1104) were plated into each well with or without recombi-
nant human IGFBP-6,11 human VEGF 165 (R&D System,
Minneapolis, MN), and/or human pigment epithelium-
derived factor (PEDF) (ProSpec-Tany Techno Gene, East
Brunswick, NJ). After 12 h incubation, a picture was taken to
cover the entire surface area of each well using a phase-con-
trast microscope. The number of total nodes and tube length
were measured. The total node number in the control group
(BD Matrigel) is 40–56/well. The results are expressed as a
percentage of the control group.
Plasmid construction, capped mRNA synthesis and
microinjection
To study the effects of IGFBP-6 on angiogenesis in zebraﬁsh
embryos, a DNA fragment containing the open reading frame
(ORF) of human IGFBP-6 (with the stop codon deleted) was
ampliﬁed by RT-PCR (forward primer 50-TTGGATCCGCC
ACCATGACCCCCC-30and reverse primer 50-TGCGAAT
TCCGCC GCTACTCCCA-30). The ampliﬁed PCR product
was digested with EcoR I and BamH I and subcloned into
the pCS2-eGFP vector18 to create pCS2-hIGFBP-6:eGFP. The
construct was veriﬁed by DNA sequencing. The construction
of zebraﬁsh IGFBP-6b expression plasmids was reported
recently.16 Capped mRNA was synthesized using a mMES-
SAGE mMACHINE kit (Ambion, Austin, TX).
Microinjection and in vivo angiogenesis assay in zebraﬁsh
To visualize and quantify the effect of IGFBP-6 on angiogen-
esis in zebraﬁsh embryos, capped mRNA was microinjected
into ﬂk1:GFP transgenic zebraﬁsh embryos19 as reported pre-
viously.15 After injection, embryos were placed in embryo-
rearing solution and kept at 28.5C. Live embryos were
imaged at 24 and 30 hpf. GFP mRNA and phenol red
injected embryos were used as controls.
In vivo tumor angiogenesis experiments
Xenografting experiments were performed as described previ-
ously.14 Brieﬂy, empty vector or human IGFBP-6 transfected
Rh30 cells (1  107 per mouse) were injected subcutaneously
into 5–6 week old female athymic BALB/c nude mice. Five con-
trol and four IGFBP-6-overexpressing mice were studied. Ani-
mal care, feeding, maintenance and surgery have been reported
previously.14 After 27 d, mice were sacriﬁced. Xenografts were
excised and ﬁxed in formalin. Parafﬁn sections (4 lm) were cut
and stained with hematoxylin and eosin. Blood vessels, as
deﬁned by erythrocyte-containing luminal structures, were
counted in 6-10 ﬁelds at 100magniﬁcation in each tumor.
Statistics
Data are shown as mean 6 standard error (SE). Differences
among groups were analyzed by one-way analysis of variance
(ANOVA) followed by Fisher’s LSD post-hoc test or by
unpaired t-test (SPSS, Chicago, IL).
Results
Hypoxia up-regulates IGFBP-6 expression in vascular
endothelial cells through HIF-1
To determine the possible effect of hypoxia on IGFBP-6
expression, human umbilical vascular endothelial cells
(HUVECs) were subjected to hypoxia (1% O2) treatment for
up to 60 h. RNA was isolated and IGFBP-6 mRNA levels
were determined by qRT-PCR. As shown in Figure 1a, hy-
poxia treatment resulted in a signiﬁcant increase in IGFBP-6
mRNA levels in HUVECs after 48 and 60 h (Fig. 1a). Next,
HUVEC cells were treated with various concentrations of the
hypoxia mimetic CoCl2. CoCl2 can activate hypoxia-depend-
ent pathways under normal oxygen levels by stabilizing HIF-
1a and is often used as a hypoxia mimetic. CoCl2 signiﬁ-
cantly increased IGFBP-6 mRNA levels at 100 and 200 lM
(Fig. 1b). Similar induction of IGFBP-6 by hypoxia and
CoCl2 was also observed by RT-PCR in HUVECs and rat
brain vessel endothelial cells (Supporting Information Fig.
S1). Further analyses showed that hypoxia (12 h) and CoCl2
(6 h)-treatment markedly increased HIF-1a levels in
HUVECs (Fig. 1c) and increased the expression of PDK1
(Supporting Information Fig. S1), a well known HIF-1 target
gene.1–3 Sequence analysis of the human IGFBP-6 promoter
suggested that there are eight canonical HREs located in the
promoter region of human IGFBP-6 gene: ﬁve in the forward
orientation and three in the reverse orientation (Fig. 1d).
These results suggest that hypoxia induces the expression of
IGFBP-6 in human and rodent vascular endothelial cells
(VECs), likely via a HIF-1-mediated mechanism.
IGFBP-6 inhibits angiogenesis through an IGF-independent
mechanism in vitro
We next examined the effect of IGFBP-6 on angiogenesis
using an in vitro capillary-like tube formation assay. VECs
can form blood vessel networks when grown on Matrigel.17
As shown in Figure 2a, when grown on BD matrigel matrix
phenol red free, HUVEC cells formed highly organized capil-
lary-like networks. Addition of IGFBP-6 resulted in fewer
and partially formed capillary-like structures (Fig. 2a). To
quantify the IGFBP-6 effect, mean tube length and node
number were determined. As shown in Figure 2b, IGFBP-6
signiﬁcantly decreased tube length at concentrations of 500
ng/mL (61 6 8% of control, p < 0.01) and 1,000 ng/mL (64
6 5% of control, p < 0.05). Similarly, IGFBP-6 signiﬁcantly
decreased node number compared to the control group (Fig.
2c, p < 0.01).
To determine whether the inhibitory effects of IGFBP-6
on angiogenesis are IGF-independent, we tested the activity
of mIGFBP-6, an IGFBP-6 mutant that has at least 10,000-
fold lower binding afﬁnity for IGF-II than native IGFBP-6.11
As shown in Figure 3, this non-IGF binding mutant IGFBP-6
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had essentially the same inhibitory activity as native IGFBP-
6. The mean tube length in the presence of 500 ng/mL
mIGFBP-6 was 57 6 2% of the control level (p < 0.001) and
the node number was 62 6 6% of control (p < 0.01). Similar
results were obtained when 1,000 ng/mL mIGFBP-6 was
added (Fig. 3). These in vitro results suggest that IGFBP-6
inhibits angiogenesis through an IGF-independent
mechanism.
IGFBP-6 inhibits VEGF-stimulated angiogenesis in vitro
We next investigated the functional relationship between
IGFBP-6 and VEGF. As mentioned earlier, hypoxia promotes
angiogenesis by inducing angiogenesis-promoting molecules
such as VEGF. Human PEDF, which inhibits angiogenesis,
was used as a control. As shown in Figure 4, addition of
VEGF165 resulted in a signiﬁcant increase in the average tube
length and the node number. As expected, PEDF signiﬁcantly
decreased in both parameters (Fig. 4). PEDF reduced VEGF-
induced angiogenesis to or below the basal levels (Fig. 4).
Addition of IGFBP-6 with VEGF165 also abolished VEGF-
stimulated angiogenesis. In fact, addition of IGFBP-6 with
VEGF165 signiﬁcantly reduced the average tube length and
node number below control values (Fig. 4). These results sug-
gest that IGFBP-6 inhibits basal as well as VEGF-stimulated
angiogenesis in vitro.
IGFBP-6 inhibits embryonic angiogenesis in vivo and this
action is conserved in zebraﬁsh
To test the effect of IGFBP-6 in an in vivo setting, capped
mRNA encoding human IGFBP-6 was synthesized and
injected into ﬂk1:GFP embryos. The ﬂk1:GFP transgenic
zebraﬁsh line is widely used for studying vascular develop-
ment. In this line, GFP expression, driven by the ﬂk1 gene
promoter, is exclusively expressed in vascular epithelial cells
in the developing vasculature,19 thus permitting visualization
of the developing blood vessels in vivo (Fig. 5a). Phenol red
was injected as control. As shown in Figure 5a, embryos
injected with human IGFBP-6 mRNA had fewer inner seg-
mental vessels (ISV) compared to embryos injected with phe-
nol red or intact embryos (Fig. 5b). As shown in Figure 5b,
the mean relative number of ISVs in the intact control group
was 100 6 5% at 30 hpf. A similar value (100 6 3%) was
obtained in the phenol red injected group. Injection of GFP
mRNA also had no effect (not shown). In contrast, human
IGFBP-6 signiﬁcantly decreased relative ISV number to 54 6
5% of control (p < 0.0001). These results, consistent with the
Figure 1. Hypoxia up-regulates IGFBP-6 gene expression in cultured human umbilical vascular endothelial cells (HUVECs) through an HIF-1-
mediated mechanism. (a) Hypoxia treatment increases IGFBP-6 mRNA levels. Cells were cultured under hypoxia (1% O2) for the indicated
time. RNA was isolated and IGFBP-6 mRNA levels were determined by real-time quantitative PCR and normalized for b-actin mRNA levels.
Values are shown as mean 6 SE (n ¼ 4); *p < 0.05 vs. 0 h. (b) CoCl2, a chemical HIF-1 inducer, increases IGFBP-6 mRNA expression
levels. HUVECs were treated with the indicated concentrations of (lM) CoCl2 for 5 h. Results are mean 6 SE (n ¼ 3); *p < 0.05 vs. control.
(c) Hypoxia and CoCl2 treatment increases nuclear HIF-1a levels. HUVECs were subjected to hypoxia (0.1%) for 12 h or 500 lM CoCl2 for 6
h. The nuclear protein was prepared and analyzed by Western blot using the indicated antibodies. D) Human IGFBP-6 gene has eight
canonical HRE and 14 putative HAS sites in the promoter/enhancer region.
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in vitro data, suggest that human IGFBP-6 inhibits angiogen-
esis in this in vivo model.
To determine whether this anti-angiogenic activity is con-
served in zebraﬁsh, we prepared capped mRNA for the
zebraﬁsh igfbp-6b gene and injected it into ﬂk1:GFP embryos.
As shown in Figure 5b, zebraﬁsh IGFBP-6b signiﬁcantly
inhibited embryonic vascular development (37 6 5%, p <
0.001). These results suggest that IGFBP-6 is an anti-angio-
genic factor in vivo, and this action is conserved between
human and zebraﬁsh IGFBP-6.
IGFBP-6 inhibits rhabdomyosarcoma xenograft
angiogenesis
We next investigated the role of IGFBP-6 in tumor angiogen-
esis by xenografting empty vector- or human IGFBP-6-trans-
fected Rh30 human rhabdomyosarcoma cells into athymic
BALB/c nude mice. We previously showed that overexpres-
sion of human IGFBP-6 in these tumor cells inhibits cell pro-
liferation and promotes apoptosis in vitro and reduces xeno-
graft growth in vivo.14 After 27 d, tumor volume of the
IGFBP-6-transfected xenografts was 60% lower than that of
vector control xenografts (0.34 6 0.08 vs. 0.86 6 0.06 cm2, p
< 0.05), conﬁrming our previous results.14 Blood vessel den-
sity, as deﬁned by erythrocyte-containing luminal structures
per ﬁeld, was quantiﬁed. Vessel density was 52% lower in
IGFBP-6-transfected xenografts than in vector control xeno-
grafts (4.3 6 0.5 vs. 8.9 6 1.2 vessels/ﬁeld, p < 0.05, Fig. 6),
suggesting that IGFBP-6 inhibits tumor angiogenesis in this
in vivo model.
Discussion
In this study, we have provided several lines of experimental
evidence supporting the notion that IGFBP-6 is an hypoxia-
inducible gene that plays a negative role in hypoxia-induced
tumor angiogenesis. We show that prolonged hypoxia indu-
ces IGFBP-6 expression in human and rat VECs, likely via
Figure 2. IGFBP-6 inhibits angiogenesis in vitro. (a) Tube formation assay was performed using HUVECs in the absence (panel a) or
presence of IGFBP-6 (panel b: 500 ng/mL, and panel c: 1,000 ng/mL) on culture dishes coated with BD Matrigel. Representative
micrographs are shown. The effect of IGFBP-6 was quantiﬁed by measuring the average tube length (b) and node number (c). Results are
expressed as a percentage of control (mean 6 SE, n ¼ 9; *p < 0.05; **p < 0.01 vs. control).
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HIF-1 activation. Our in vitro assays, using cultured human
HUVECs, and in vivo studies, using ﬂk1:GFP zebraﬁsh
embryos, suggest that IGFBP-6 is a potent anti-angiogenic
molecule. This action is conserved across species and is IGF-
independent. Furthermore, we provide direct evidence for an
inhibitory role of IGFBP-6 in tumor angiogenesis in Rh30
human rhabdomyosarcoma xenografts.
VECs are critical components of the vasculature and play
a crucial role in the maintenance of vascular integrity. These
cells are hypoxia tolerant and can divide under hypoxic con-
ditions. There is a large body of published data suggesting
that major components of the IGF signaling pathway are
expressed and functional in VECs.20 IGFs are evolutionarily
conserved polypeptides that regulate a wide range of cellular
processes including mitogenesis, differentiation, migration
and survival.21 These actions are largely mediated through
the IGF-I receptor (IGF-IR), a receptor tyrosine kinase.
Ligand binding of the IGF-IR activates a number of major
signaling pathways, including the Ras-MAPK and the PI3
kinase-Akt pathways. IGF signaling has been implicated in
hypoxia-induced tumor angiogenesis.20 IGF-I stimulates
HIF-1a expression in endothelial cells via the PI3 kinase/
mTOR signaling pathway.22 IGF-I also stimulates VEGF
expression and secretion via HIF-1-dependent and -inde-
pendent mechanisms.23 Furthermore, pharmacological
blockade or tissue-speciﬁc knockout of the IGF-IR decreased
retinal neovascularization.24,25
Cultured mammalian VECs express IGFBP 2-6.12,26,27
IGFBPs synthesized by VECs are involved in transfer of IGFs
across the VEC barrier.28,29 IGFBPs bind IGFs and inhibit or
potentiate their actions in the vasculature.20 Han and
coworkers have shown that IGFBP-6 mRNA expression was
very low in cultured bovine VECs and increased with expo-
sure to hypoxia.12 The mechanism underlying this hypoxia
induction, however, was not studied. In this study, we have
extended this observation to human and rat VECs, suggesting
Figure 3. The anti-angiogenic action of IGFBP-6 is IGF-independent. (a) Tube formation assay was performed using HUVECs in the absence
(panel a) or presence of mIGFBP-6, an IGFBP-6 mutant with impaired IGF binding (panel b: 500 ng/mL, and panel c: 1,000 ng/mL). The
effect was quantiﬁed by measuring the average tube length (b) and node number (c). Results are expressed as a percentage of control
(mean 6 SE, n ¼ 6; **p < 0.01; ***p < 0.0001 vs. control; ns, not signiﬁcantly different).
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the up-regulation of IGFBP-6 expression in VECs is con-
served across species. Furthermore, we provide evidence that
HIF-1 activation is likely involved in hypoxia-induced
IGFBP-6 gene expression. Hypoxia or CoCl2 treatments
increased nuclear HIF-1a levels and increased expression of
established HIF-1 target genes such as PDK1. Sequence anal-
ysis of the human IGFBP-6 gene showed that there are eight
canonical HREs located in the promoter region: ﬁve in the
forward orientation and three in the reverse orientation. It
has been proposed that cooperative interactions between the
HRE and an adjacent HIF-1 ancillary sequence (HAS) are
critical to confer hypoxia responsiveness.15 In the promoter
region of human IGFBP-6, we found 14 putative HAS, six in
the forward orientation and eight in the reverse orientation.
HIF-1 has also been shown to induce the expression of a
related gene, IGFBP-1, and hypoxia increased IGFBP-1
expression in the liver through an HRE located in intron 2 of
its gene.30 More recent studies show that the induction of
IGFBP-1 gene expression by hypoxia is mediated through
HIF-1 both in vitro and in vivo.15 There is a clear temporal
Figure 5. Human and zebraﬁsh IGFBP-6 inhibits blood vessel
formation in zebraﬁsh embryos in vivo. (a) A 30-hr post fertilization
(hpf) ﬂk1:GFP transgenic zebraﬁsh embryo. The upper panel is a
bright ﬁeld view and lower panel is a GFP view. Arrows indicate
inner segmental vessels (ISV). (b) 1–2 cell stage ﬂk1:GFP
transgenic zebraﬁsh embryos were microinjected with phenol red,
capped mRNA encoding human IGFBP-6 or zebraﬁsh IGFBP-6
(zIGFBP-6b). The embryos were raised to 30 hpf and the number of
inner segmental vessels (ISV) was counted. Results are expressed
as a percentage of control (mean 6 SE; n ¼ 3; *p < 0.05;
***p < 0.001). [Color ﬁgure can be viewed in the online issue,
which is available at wileyonlinelibrary.com.]
Figure 4. IGFBP-6 inhibits both basal and VEGF-stimulated
angiogenesis. Tube formation assay was performed using HUVECs
in the presence of VEGF (25 ng/mL), PEDF (916 ng/mL), IGFBP-6
(1,000 ng/mL), VEGF þ PEDF and VEGF þ IGFBP-6. The average
tube length (a) and node number (b) were determined and are
expressed as a percentage of the control group (mean 6 SE,
n ¼ 3). Groups labeled with different letters are statistically
different from each other at p < 0.01.
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difference between IGFBP-1 and IGFBP-6 regulation by hy-
poxia: hypoxia increases IGFBP-1 gene expression rapidly in
liver/hepatocytes, whereas the up-regulation of the IGFBP-6
gene was not observed until 48 h of hypoxia. This timing is
interesting as it implies that IGFBP-6 induction by hypoxia
may act as a negative feedback mechanism in hypoxia-
induced angiogenesis.
A number of mechanisms underlying the inhibitory actions
of IGFBP-6 on tumor growth have been suggested. IGFBP-6
has been shown to inhibit tumor cell proliferation and increase
apoptosis, most likely by binding to and inhibiting IGF-II
actions.10,11,14 IGFBP-6 has been recently reported to interact
with Ku80, a DNA-end binding protein, in the cytoplasm to
regulate cell survival, and this effect may be IGF-dependent.31
IGFBP-6 acts as an effector of the tumor suppressor gene sem-
aphorin 3B in lung cancer cells, although IGF-II partially abro-
gated its effects.32 A number of recent studies also indicate that
IGFBP-6 may suppress tumor growth via IGF-independent
actions. IGFBP-6 has a functional nuclear localization signal
and is capable of translocation to the nucleus in an IGF-inde-
pendent manner.33 IGFBP-6 inhibited nasopharyngeal carci-
noma cell proliferation, invasion and metastasis by directly
binding to the promoter of the tumor suppressor EGR-1 and
increasing its expression; IGF-dependence of this effect was
not directly studied.34 In contrast to the above studies, IGFBP-
6 has also been shown to promote rhabdomyosarcoma and co-
lon cancer cell migration via p38 MAPK and crosstalk with
other MAPKs in an IGF-independent manner.11,35
The results of our study suggest an additional and novel
mechanism by which IGFBP-6 inhibits tumor growth. Our in
vitro and in vivo data show that IGFBP-6 is a potent angio-
genesis inhibitor. This action is IGF-independent and is evo-
lutionarily conserved in human and ﬁsh. Ongoing solid tu-
mor growth requires angiogenesis which is driven by relative
hypoxia.36 Inhibition of hypoxia-induced angiogenesis by
IGFBP-6 may, therefore, contribute to its tumor suppressor
properties. There are several plausible mechanisms by which
IGFBP-6 inhibits angiogenesis: (i) since IGFBP-6 suppresses
VEGF-induced tube formation when added together in cul-
tured HUVECs, IGFBP-6 may inhibit VEGF action by
directly binding to VEGF itself and/or affect VEGF receptor-
mediated signaling; (ii) IGFBP-6 has been shown to activate
p38 MAPK in an IGF-independent manner and this is
required for its ability to promote rhabdomyosarcoma and
colon cancer cell migration.35 It is possible that IGFBP-6
inhibits angiogenesis via a similar mechanism; (iii) IGFBP-6
has a functional nuclear localization signal and is capable of
translocation to the nucleus.33 A recent study reports that
IGFBP-6 inhibits nasopharyngeal carcinoma cell proliferation,
invasion and metastasis by directly binding to the promoter
of the tumor suppressor gene EGR-1 and increasing its
expression.34 The possible involvement of nuclear IGFBP-6
in the anti-angiogenic action cannot be ruled out. Future
studies aimed at elucidating the molecular basis of IGF-inde-
pendent inhibition of angiogenesis by IGFBP-6 should
deepen our understanding of hypoxia-regulated tumor
Figure 6. IGFBP-6 inhibits angiogenesis in Rh30 human rhabdomyosarcoma xenografts in vivo. Nude mice were injected with Rh30 cells
that had been stably transfected with an IGFBP-6-expressing (n ¼ 4) or control (n ¼ 5) vector. After 27 d, tumors were excised and ﬁxed.
Parafﬁn sections were cut and stained with hematoxylin and eosin. (a) A representative view of xenografts from the control (panel a) and
IGFBP-6-overexpressing Rh30 cells (panel b). Some blood vessels, deﬁned as erythrocyte-containing luminal structures, are indicated by
arrows. (b) Quantitative results. Blood vessels were counted in 6–10 ﬁelds at 100 magniﬁcation in each tumor. Results are shown as
mean 6 SE, n ¼ 4–5; *p < 0.05. [Color ﬁgure can be viewed in the online issue, which is available at wileyonlinelibrary.com.]
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angiogenesis. It should be pointed out that our current model
on the hypoxia-induced IGFBP-6 expression in VECs and
the anti-angiogenic action of IGFBP-6 is based on results
from gain-of-functional experiments, either by adding large
amounts of puriﬁed IGFBP-6 to cultured human cells in vitro
or by overexpressing IGFBP-6 in animal tissues in vivo.
Future studies are needed to determine whether the local lev-
els of IGFBP-6 in tumor vasculature are sufﬁciently high to
cause a signiﬁcant decrease in angiogenesis in vivo. It will
also be interesting to test whether knockdown of IGFBP-6 in
VECs using short double-stranded RNA (siRNA) will
enhance hypoxia-induced angiogenesis and increase tumor
growth. Moreover, tissue-speciﬁc IGFBP-6 knockout mouse
lines will be needed to determine the physiological role of the
hypoxia-induced IGFBP-6 expression by VECs in vivo.
Understanding the signaling pathways leading to the negative
regulation of angiogenesis will likely provide important tools
to develop novel therapeutic strategies to hinder deregulated
tumor angiogenesis.
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